

## Technology Appraisal Committee B Interests Register

Topic: Spesolimab for treating generalised pustular psoriasis flares [ID3963]

Publication Date: 19 June 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David McAlister	TAC Committee Member	Non-Financial Professional interests	<p>Access BI trials via the Vivli repository for non-commercial research. Access Takeda trials via the Vivli repository for non-commercial research</p> <p>David has access to individual-level participant data for clinical trials sponsored by BI of a number of their investigational products. He uses this data in his academic research. The data was made available after review by an independent steering committee. BI are entitled by data sharing agreement to comment on academic outputs made using the data before they are released publicly, but are not able to require changes.</p>	10/03/2025 12/12/2024	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Professor Catherine Smith	Clinical Expert	Direct – non-financial	British Association of Dermatologists – Chair and committee member on multiple guidelines, including BAD	02/04/2025	It was agreed that Professor Smith's declaration would not

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Guidelines on Biologic Therapy in Psoriasis – latest update 2023</p> <p>Expert advisor for EMA</p> <p>Member of International Psoriasis Council</p> <p>Member on recent COVID-19 NICE guideline for Dermatology (which covered use of immunosuppressants, biologics)</p>	12/12/2024	prevent her from providing expert advice to the committee.
		Indirect - Financial	<p>GSTT-PI/co-investigator on commercially sponsored clinical trial work or investigation-led studies including AbbVie, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Roche (all completed 2019). Our MRC founded consortium (PSORT) has multiple industry partners including: AbbVie, Sanquin, Qiagen, Pfizer, Novartis, MedImmune, Janssen, Celgene (list not exhaustive as partners change please see psort.org) 7/04/2014 → 31/05/2021. All income managed via the Trust/KCL. No personal</p>	02/04/2025 12/12/2024	It was agreed that Professor Smith's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>pecuniary interest. No advisory board/paid expert/invited speaker engagements.</p> <p>IMI-funded collaborative network of clinicians, researchers and industry along with patient organisations and other stakeholders (BIOMAP). Multiple industry partners including (list not exhaustive as partners change please see <a href="https://www.biomap-imi.eu/">https://www.biomap-imi.eu/</a>) : Sanofi, LEO Pharma, Boehringer Ingelheim, Pfizer, UCB Pharma. 1/04/2019 → 31/03/2025</p> <p>IMI funded collaborative network of clinicians, researchers and industry along with patient organisations and other stakeholders (HIPPOCRATES). Multiple industry partners (please see <a href="https://www.hippocrates-imi.eu/">https://www.hippocrates-imi.eu/</a> for an up to date list. 1/07/2021 → 30/06/2026</p>		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Decoding the molecular and cellular resolution of skin inflammation in eczema (co-I)</p> <p>Open Targets – Sanger (multiple industry partners).</p> <p>1/02/2024 → 31/01/2026</p> <p>MRC funded research contract studentship (Examining IL-36 signaling as a therapeutic target in pustular psoriasis) which I am a Co-I. Funded by Boehringer Ingelheim. No personal pecuniary interest. 1/10/2018 → 30/09/2022</p> <p>MRC funded research contract studentship, funded through AstraZeneca. I am co-supervisor for PhD studentship. 1/10/2023 → 30/09/2027</p> <p>Treatment of Pustular Psoriasis with IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies.</p>		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>(NIHR funded with drug supplied by SOBI) – now complete.</p> <p>NIHR HTA programme grant for RCT in Atopic dermatitis, with a 4th arm fully funded by Pfizer.</p>		
Helen McAteer	Patient Expert	Indirect - Financial	<p>Psoriasis Association has received funding from Boehringer Ingelheim - £2,000 towards annual conference costs (they and the other companies who supported the event had no control / input to the programme agenda).</p> <p>Other pharmaceutical funding in the last 12 months includes:-</p> <p>Abbvie (£600 – Honorarium)</p> <p>Bristol Myers Squibb (BMS) (£4,500 – Core funding and Conference costs)</p> <p>Janssen (£2,500 Conference costs)</p> <p>LEO Pharma (£2,000 – Core funding)</p>	02/04/2025	It was agreed that Ms McAteer’s declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Medac Pharma (£2,000 – Core funding)</p> <p>UCB (£5,160 – Core funding, Conference costs and honorarium)</p> <p>The Psoriasis Association has a policy that no more than 15% of income can come from the pharmaceutical industry</p>		

DRAFT